A $25 million upfront payment is a modest headline number for a deal that carries up to $420 million in milestone value, and the gap between those two figures tells you exactly how much work remains in China before Aligos Therapeutics captures the real prize. The company confirmed receipt of the cash from Xiamen Amoytop Biotech under their existing exclusive license for pevifoscorvir sodium in Greater China, covering Mainland China, Taiwan, Hong Kong, and Macau. The same announcement brought a more consequential piece of news: China’s NMPA granted Breakthrough Therapy Designation for pevifoscorvir sodium, which clears the path for a 130-day priority NDA review once the program matures to that stage.
The strategic pairing here is worth attention. Amoytop is not simply a passive territory licensee. The company already has its own hepatitis B asset, Pegbing, which China approved in October 2025 as a domestically developed injectable aimed at functional cure. That approval positions Amoytop as an operator with commercial infrastructure and regulatory credibility in this exact disease area, not just a check-writing partner. Aligos is layering pevifoscorvir sodium, a Class E capsid assembly modulator with Phase 1 data suggesting reductions in the cccDNA reservoir, onto a partner that already understands the reimbursement and commercial terrain in China’s HBV market. That is not a coincidence of geography; it is a deliberate co-development architecture.
Aligos retains all rights in the United States, Europe, South Korea, Japan, and other markets outside Greater China, which means the partnership does not dilute the asset’s value in the highest-margin geographies. The company is also advancing its antisense oligonucleotide ALG-170675 into the clinic in China through the same relationship, with that IND-equivalent entry targeted for Q3 2026. Stacking two mechanisms through one partnership reduces duplicated infrastructure costs and deepens the commercial relationship in a way that protects Aligos if either asset runs into trial headwinds.
The single marker worth watching now is whether ALG-170675 enters the China clinic on that Q3 2026 schedule. A slip there would reveal execution risk in the partnership’s operational machinery; an on-time initiation would confirm that Amoytop can absorb and advance two programs simultaneously, meaningfully raising the probability that the full $420 million milestone stack is actually reachable.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
